Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Wall Street Unhappy with Mindray Medical’s Q3

publication date: Nov 11, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

On the face of it, the Q3 financial report issued by Mindray Medical International was very positive. Revenues were up 94% at $146.5 million and non-GAAP net income climbed a smaller but still respectable 48% to $33.7 million. Nevertheless, Mindray’s stock price suffered in the aftermath, falling $4.02 to $19.91, a 17% decline and a price that is considerably lower than its $45.10 high this year. Why were investors so disappointed? More details...

Stock Symbol: (NYSE: MR)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners